Advertisement
Screener

Biomea Fusion, Inc. (BMEA) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

Biomea Fusion, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

Biomea Fusion, Inc. (BMEA) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$20.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2026-08-05

  • Biomea Fusion, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$8.33M.
  • Biomea Fusion, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$12.41M.
  • Biomea Fusion, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $4.61M.
  • Biomea Fusion, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$16.41M.
  • Biomea Fusion, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$61.80M.
  • Biomea Fusion, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$138.43M.
  • Biomea Fusion, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$117.25M.
  • Biomea Fusion, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$81.83M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month
2026-06-30-$8.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$20.74M
10-Q · filed 2026-08-05
-$16.13M
derived: sum of 3 quarters · filed 2026-08-05
-$32.54M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31-$12.41M
10-Q · filed 2026-05-11
-$7.80M
derived: sum of 2 quarters · filed 2026-05-11
-$24.21M
derived: sum of 3 quarters · filed 2026-05-11
-$44.95M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$4.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
-$11.79M
derived: sum of 2 quarters · filed 2026-03-24
-$32.53M
derived: sum of 3 quarters · filed 2026-08-05
-$61.80M
10-K · filed 2026-03-24
2025-09-30-$16.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$37.15M
derived: sum of 2 quarters · filed 2026-08-05
-$66.41M
10-Q · filed 2025-11-04
-$95.71M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30-$20.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$50.00M
10-Q · filed 2026-08-05
-$79.30M
derived: sum of 3 quarters · filed 2026-08-05
-$112.09M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$29.26M
10-Q · filed 2026-05-11
-$58.56M
derived: sum of 2 quarters · filed 2026-05-11
-$91.35M
derived: sum of 3 quarters · filed 2026-05-11
-$128.63M
derived: sum of 4 quarters · filed 2026-05-11
2024-12-31-$29.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
-$62.09M
derived: sum of 2 quarters · filed 2026-03-24
-$99.36M
derived: sum of 3 quarters · filed 2026-03-24
-$138.43M
10-K · filed 2026-03-24
2024-09-30-$32.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$70.06M
derived: sum of 2 quarters · filed 2025-11-04
-$109.12M
10-Q · filed 2025-11-04
-$144.01M
derived: sum of 4 quarters · filed 2026-03-24
2024-06-30-$37.28M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$76.34M
10-Q · filed 2025-08-05
-$111.22M
derived: sum of 3 quarters · filed 2026-03-24
-$139.65M
derived: sum of 4 quarters · filed 2026-03-24
2024-03-31-$39.06M
10-Q · filed 2025-05-05
-$73.94M
derived: sum of 2 quarters · filed 2026-03-24
-$102.37M
derived: sum of 3 quarters · filed 2026-03-24
-$127.27M
derived: sum of 4 quarters · filed 2026-03-24
2023-12-31-$34.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
-$63.31M
derived: sum of 2 quarters · filed 2026-03-24
-$88.20M
derived: sum of 3 quarters · filed 2026-03-24
-$117.25M
10-K · filed 2026-03-24
2023-09-30-$28.43M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29
-$53.32M
derived: sum of 2 quarters · filed 2024-10-29
-$82.37M
10-Q · filed 2024-10-29
-$107.69M
derived: sum of 4 quarters · filed 2025-03-31
2023-06-30-$24.89M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31
-$53.94M
10-Q · filed 2024-07-31
-$79.26M
derived: sum of 3 quarters · filed 2025-03-31
-$102.15M
derived: sum of 4 quarters · filed 2025-03-31
2023-03-31-$29.05M
10-Q · filed 2024-05-02
-$54.37M
derived: sum of 2 quarters · filed 2025-03-31
-$77.25M
derived: sum of 3 quarters · filed 2025-03-31
-$94.51M
derived: sum of 4 quarters · filed 2025-03-31
2022-12-31-$25.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
-$48.20M
derived: sum of 2 quarters · filed 2025-03-31
-$65.46M
derived: sum of 3 quarters · filed 2025-03-31
-$81.83M
10-K · filed 2025-03-31
2022-09-30-$22.89M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30
-$40.15M
derived: sum of 2 quarters · filed 2023-10-30
-$56.51M
10-Q · filed 2023-10-30
-$71.22M
derived: sum of 4 quarters · filed 2024-03-28
2022-06-30-$17.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31
-$33.62M
10-Q · filed 2023-07-31
-$48.33M
derived: sum of 3 quarters · filed 2024-03-28
-$60.94M
derived: sum of 4 quarters · filed 2024-03-28
2022-03-31-$16.37M
10-Q · filed 2023-05-02
-$31.08M
derived: sum of 2 quarters · filed 2024-03-28
-$43.68M
derived: sum of 3 quarters · filed 2024-03-28
-$52.08M
derived: sum of 4 quarters · filed 2024-03-28
2021-12-31-$14.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
-$27.32M
derived: sum of 2 quarters · filed 2024-03-28
-$35.72M
derived: sum of 3 quarters · filed 2024-03-28
-$41.57M
10-K · filed 2024-03-28
2021-09-30-$12.61M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
-$21.00M
derived: sum of 2 quarters · filed 2022-11-07
-$26.86M
10-Q · filed 2022-11-07
-$30.36M
derived: sum of 4 quarters · filed 2023-03-28
2021-06-30-$8.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01
-$14.25M
10-Q · filed 2022-08-01
-$17.75M
derived: sum of 3 quarters · filed 2023-03-28
-$18.88M
derived: sum of 4 quarters · filed 2023-03-28
2021-03-31-$5.85M
10-Q · filed 2022-05-16
-$9.35M
derived: sum of 2 quarters · filed 2023-03-28
-$10.48M
derived: sum of 3 quarters · filed 2023-03-28
-$10.78M
derived: sum of 4 quarters · filed 2023-03-28
2020-12-31-$3.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28
-$4.63M
derived: sum of 2 quarters · filed 2023-03-28
-$4.93M
derived: sum of 3 quarters · filed 2023-03-28
-$5.32M
10-K · filed 2023-03-28
2020-09-30-$1.14M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
-$1.43M
derived: sum of 2 quarters · filed 2021-11-03
-$1.83M
10-Q · filed 2021-11-03
2020-06-30-$293.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11
-$691.00K
10-Q · filed 2021-08-11
2020-03-31-$398.00K
10-Q · filed 2021-05-27
2019-12-31-$1.20M
10-K · filed 2022-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
Equillium, Inc. (EQ)United States$0.109B-11.27
GENELUX Corp (GNLX)United States$0.110B-3.83
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
ProMIS Neurosciences Inc. (PMN)$0.102B
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Anixa Biosciences Inc (ANIX)United States$0.096B